Australian drug delivery company Acrux has received support from European medical authorities for its first animal health product.
The European Committee for Medicinal Products for Veterinary Use (CVMP) granted marketing authorization for the drug Recuvyra, a skin solution for dogs containing the active ingredient Fentanyl that controls pain after orthopedic and soft tissue surgery.
The solution was developed under license by the animal health unit of pharmaceutical giant Eli Lilly and Company, called Elanco.
Continued Cooperation with Eli Lilly
Upon approval of the marketing authorization, Acrux will receive an initial payment of AU$500,000 from the CVMP and will be entitled to royalties on product sales.
Drug giant Eli Lilly holds the exclusive licence to commercialize and develop Acrux’s transdermal animal health products. Recuvyra is expected to receive marketing authorization within 90 days.
The dog treatment’s launch in Europe will be the latest drug product from Eli Lilly and Acrux, after last year’s release of the topical male testosterone solution Axiron.
“Following the recent launch by Lilly of Axiron in the United States, this adds further momentum to Acrux’s partnership with Lilly,” said Richard Treagus, Acrux CEO.
Key Players – Veterinary Health Market
- Abaxis, Alpharma, BASF, Bayer Animal Health, Biocurex, BioVet, Boehringer Ingelheim, Elanco Animal Health, Janssen Pharmaceutica, Merck, Neogen Corporation, Novartis Animal Health, PETCO Animal Supplies, Pfizer Animal Health, Randox, Sanofi-Aventis, Teva Pharmaceutical Industries